Hans Kreipe

Medizinische Hochschule Hannover — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

78h-index24.3kcitations711works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(120), HER2/EGFR in Cancer Research(106), Myeloproliferative Neoplasms: Diagnosis and Treatment(105), Acute Myeloid Leukemia Research(94), Cancer Genomics and Diagnostics(64)

Publications703 total

Supplementary Table S2 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Supplementary Table S4 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Supplementary Table S3 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
"Supplementary Table S5 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Supplementary Table S1 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Supplementary Figure S3 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Supplementary Figure S2 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
"Supplementary Table S6 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Supplementary Figure S1 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
2025Open Access
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Clinical Cancer Research·2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
JCO Clinical Cancer Informatics·2025
<scp>NMD</scp> ‐insensitive <scp> <i>CDH1</i> </scp> mutation as a mechanism for retained E‐cadherin protein expression in lobular carcinoma in situ ( <scp>LCIS</scp> )
Histopathology·2025Open Access
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders
Journal of Clinical Investigation·2025· 2 citedOpen Access
Adultes Rhabdomyom
Die Pathologie·2025Open Access
Use of an artificial intelligence model to predict Ki67 from H&amp;E-stained whole slides images in breast cancer.
Journal of Clinical Oncology·2025
Patient outcomes in WSG-ADAPT according to NATALEE and MonarchE risk criteria.
Journal of Clinical Oncology·2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
Journal of Clinical Oncology·2025· 1 cited
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
The Lancet Oncology·2025· 4 cited
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Molecular Cancer·2025· 4 citedOpen Access
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer
JAMA Network Open·2025· 5 citedOpen Access
page 1 of 36Next →

Frequent Co-authors

Ulrich Lehmann(11), Matthias Christgen(10), Nadia Harbeck(8), Michael Mengel(8), Oleg Gluz(7), Christoph Klein(6), Ulrike Nitz(6), Ronald Kates(6), Britta Hasemeier(5), Florian Länger(5), Bahriye Aktas(5), Cornelia Liedtke(5), Rachel Wuerstlein(5), Hermann Haller(5), Brigitte Schlegelberger(5), Wilfried Gwinner(5), Anke Schwarz(5), Daniel Kotlarz(4), Jana Diestelhorst(4), Dietmar Pfeifer(4)